X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.
Lead Product(s): mRNA vaccines
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CureVac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2021
Details:
Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Intravacc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 29, 2020
Details:
Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.
Lead Product(s): AT-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Airway Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
